1 / 36

Catecholamines

Catecholamines. Stored in vesicles Release tightly controlled Presynaptic receptors Activators include NE (  2 ) , DA (D 2 ), Ach, prostaglandins, other amines, glutamate and/or endorphins Autoreceptors important target for antidepressant drugs eg mirtazapine

kordell
Download Presentation

Catecholamines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Catecholamines • Stored in vesicles • Release tightly controlled • Presynaptic receptors • Activators include • NE (2), DA (D2), Ach, prostaglandins, other amines, glutamate and/or endorphins • Autoreceptors important target for antidepressant drugs eg mirtazapine • Amphetamines can stimulate release of stored catecholamines • Behavioural activation

  2. Vesicular Packaging • Vesicular monoamine transporter (VMAT) • VMAT1 found in adrenal medulla • VMAT2 found in brain • Both blocked by reserpine • Elevated intracellular breakdown of DA and NEebox • Low levels in brain • Sedation in animals, depressive symptoms in humans

  3. Reserpine 5mg kg-1 Plus DOPA 200mg kg-1 (Carlssen et al 1957)

  4. MAO Mono amine oxidase; COMT catechol-O-methyltransferase MOA inhibitors COMT inhibitors Eg Phenelzine, tranylcypromine Entacapone Tolcapone DAT; 5-HTT (or SERT), NAT, NET Transport blocking drugs: Cocaine - DA, - NE, - 5HTT Reboxetine -NE; tricyclic antidepressants –NE, -5HTT

  5. Post Synaptic Catecholamine Receptors • Class 2; Metabotropic; GPCR • Open ion channels and/or influence metabolism by 2nd messenger system • Receptors may down-regulate in presence of antidepressant drugs which inhibit re-uptake (eg maprotilene, bupropion)

  6. Receptor types: Dopamine • Dopamine • 5 subtypes D1 – D5 • D1, D5 similar • D2, D3, D4 separate family • D1 and D2 most common • Found in: striatum (basal ganglia) and nucleus accumbens (limbic)

  7. D1, D2 have opposite effects: activate different G proteins (Gs, Gi) Also, D2 activates G protein that opens K+ gates

  8. Dopamine Pathways I • substantia nigra (mesencephalon) • basal ganglia • Role in movement control • Parkinsonism • Antipsychotic-induced extra-pyramidal side effects NIGROSTRIATAL DA PATHWAY

  9. Dopamine Pathways II • Midbrain (VTA10) near substantia nigra •  cerebral cortex (esp. frontal cortex) •  limbic system (esp. limbic cortex, nucleus accumbens, amygdala, hippocampus • Underlies reward system MESOCORTICAL MESOLIMBIC

  10. Noradrenaline Receptor Types • Norepinephrine (and epinephrine) exert effects via two primary types: ,  adrenoreceptors • each has two subtypes 1, 2; 1, 2 • 1, 2 similar to DA D1 receptor effect • 2 similar to DA D2 receptor effect (commonly an autoreceptor) • 1 operates through phosphoinositide 2nd messenger system  Ca2+ influx within postsynaptic cell (Gq)

  11. The Locus Coeruleus

  12. LC and Vigilance Aston Jones 1985

  13. Effect of 1 and  adrenergic agonists injected into the rat medial septum on time spent awake Berridge et al 2003)

  14. 2 receptor: effect blocked by 2 antagonist (eg yohimbine) and mimicked when 2 agonist (eg clonidine) replaces NE LC (Wellman et al 1992)

  15. Serotinin: 5-hydroxytryptamine (5-HT) • “Serotonergic neurones” • Same VMAT2 • VMAT2 blocker reserpine depletes 5HT • Serotonergic autoreceptors • Somatodendritic 5-HT1A • Terminal autoreceptors 5-HT1B or 5-HT1D

  16. More similarities…….. • Release directly stimulated by amphetamine-type drugs • Para-chloramphetamine • fenfluoramine • 3,4-methylenedioxymethamphetamine (MDMA – ecstasy)

  17. 5-HT uptake also similar • 5-HT transporter • Key site of drug uptake • eg Fluoxetine (Prozac) • Antidepressant • Selective serotonin reuptake inhibitors (SSRIs) • nb MDMA and cocaine interact with 5-HTT, but not selective (also influence DA transporter)

  18. Catabolism • DA, NE metabolised by MAO and COMT • 5-HT not a catecholamine, therefore COMT not effective • MAO + 5-HT  5-hydroxyindoleacetic acid (5-HIAA) • Brain or CSF 5-HIAA used as a measure of serotonergic activity

  19. “B” 1-8: The Raphe Nuclei – in midbrain and pons Major source of seroternergic fibres: B7 Dorsal Raphe; B8 median Raphe To: all forebrain: neocortex, striatum, nucleus accumbens, thalamus, hypothalmus, and limbic structures – hippocampus, amygdala, septal area

  20. 5-HT receptors: horrible! • 15 subtypes, so far • Including: • 5-HT1 large family: 5-HT1A, 5-HT1B……etc • Smaller 5-HT2 family 5-HT2A, 5-HT2B……etc : • Plus 5-HT3, 5-HT4, 5HT5, 5-HT6, 5-HT7 • All metabotropic (class II), except • 5-HT3 – excitatory ionotropic receptor

  21. 5-HT1A Receptor: hippocampus, septum, amygdala, raphe nuclei (Gi) inhibits adenylate cyclase (cAMP Opens K+ channels • Receptor agonists • Buspirone, ipasapirone, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) • Hyperphagia (5-HT tends to reduce appetite) • Reduced anxiety • Hypothermia • Inhibits motivation to drink alcohol

  22. 5-HT2A Receptor: large numbers in cerebral cortex, also striatum, nucleus accumbens • (Gq) activates phosphoinositide 2nd messenger system • Agonists • 1-(2,5 dimethoxy-4-iodophenyl)-2-aminopropane (DOI) • Hallucinogenic (cf Lysergic acid diethylamide; LSD) • Head twitch response in rats/mice • Measure of 5-HT2A receptor stimulation • Antagonists: ketanserin, ritanserin

  23. Acetyl Choline HC-3 hemicholinium AChE blocked by (eg) Physostigmine, Neostigmine Insecticides (malathion) Nerve gas (sarin, soman)

  24. Ach central pathways Note: basal forebrain cholinergic system (BFCS)

  25. Ach Receptors • Two families • Nicotinic • Ionotropic, 5 subunits, • Muscarinic • Metabotropic • M1 – M5 • Agonists: (parasympathomimetic) eg pilocarpine • Antagonists: (parasympatholytic) eg atropine, scopolamine

  26. Glutamate: excitatory amino acid

  27. Glutamate receptors (and kainate) MGluR1- MGluR8 Phencyclidine, ketamine

  28. Roles • AMPA (selective agonist:  amino 3 hydroxy 5 methyl 4 isoxazole proprionic acid) – rapid excitation • Normal locomotor activity, motor co-ordination, learning • NMDA (N-methyl-D-aspartate) • Learning, memory, cognitive ability • MGluR1 • Normal cerebellum control of motor function • High levels of glutamate are neurotoxic • Depolarisation-induced excitotoxicity

  29. Gamma Amino Butyric Acid

  30. GABA Receptors • GABAA • Ionotropic: opens chloride channels • Classic agonist = muscimol • Macroscopia • Hyperthermia • Pupil dilation • Elevation of mood • Difficulties with concentration • Anorexia • Catalepsy, • hallucinations

  31. GABAA Antagonist • Bicuculline – best known competitive antagonist • Convulsant • Pentylenetetrazol, picrotoxin • Non competitive convulsants

  32. GABAA sensitivity to CNS depressant drugs • Benzodiazepines (BDZs), barbiturates, • Potentiates the action of GABA on GABAA • Receptors on GABAA for other ligands • Eg BDZ (diazepam = valium) “sensitises” the receptor to GABA • BDZs cannot activate the GABAA receptor on their own • No effect in the absence of GABA

  33. GABAB • Metabotropic receptor • Inhibition of cAMP • K+ opening • GABAB agonists/antagonists have no effect on GABAA • GABAB activated by selective agonist baclofen (Lioresal) • Muscle relaxant, anti-spastic agent

More Related